Abstracts tagged "rheumatoid arthritis (RA) and spondylarthropathy"

Abstract Number: 2097 • 2019 ACR/ARP Annual Meeting
Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Ufuk İlgen¹, Sezin Turan ¹, Hakan Emmungil ¹, Alper Sarı ², Abdulsamet Erden ², Levent Kilic ³, Ömer Karadağ ², Sedat Kiraz ³, Ali İhsan Ertenli ⁴, Orhan Küçükşahin ⁵, Şükran Erten ⁶, Zeynel Abidin Akar ⁷, Burak Öz ⁷, Süleyman Serdar Koca ⁸, Cemal Bes ⁹, Nilufer Alpay-Kanitez ¹⁰, Emre Tekgöz ¹¹, Seda Çolak ¹¹, Muhammet Çınar ¹¹, Sedat Yılmaz ¹¹, Veli Yazısız ¹², Mustafa Ender Terzioğlu ¹², Ayşe Bahar Keleşoğlu Dinçer ¹³, Aşkın Ateş ¹³, Rıdvan Mercan ¹⁴, Onay Gercik ¹⁵, Servet Akar ¹⁶, Mehmet Pamir Atagündüz ¹⁷, Gezmiş Kimyon ¹⁸, Emel Gönüllü ¹⁹, Emine Duygu Ersözlü ²⁰, Müge Aydın Tufan ²¹, Burcu Yağız ²², Belkıs Nihan Coşkun ²³, Yavuz Pehlivan ²², Ediz Dalkılıç ²² and Umut Kalyoncu ²⁴, ¹Trakya University, Edirne, Turkey, ²Hacettepe University, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁵Liv Hospital, Ankara, Turkey, ⁶Yıldırım Beyazıt University, Ankara, Turkey, ⁷Fırat University, Elazığ, Turkey, ⁸Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁹University of Medical Sciences, İstanbul, Turkey, ¹⁰Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, ¹¹University of Medical Sciences, Ankara, Turkey, ¹²Akdeniz University, Antalya, Turkey, ¹³Ankara University, Ankara, Turkey, ¹⁴Namık Kemal University, Tekirdağ, Turkey, ¹⁵Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁷Marmara University, İstanbul, Turkey, ¹⁸Mustafa Kemal University, Hatay, Turkey, ¹⁹Sakarya University, Sakarya, Turkey, ²⁰Adana State Hospital, Adana, Turkey, ²¹Başkent University, Adana, Turkey, ²²Uludağ University, Bursa, Turkey, ²³Uludağ University, Bursa, ²⁴Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Screening for and the treatment of latent tuberculosis is recommended in patients with inflammatory arthritides prior to biologic treatments, particularly the TNF inhibitors. The…
Abstract Number: 2532 • 2018 ACR/ARHP Annual Meeting
The Efficacy and Drug Survival of the Biosimilar Infliximab (CT–P13) Compared to the Original Reference Infliximab in Inflammatory Rheumatic Diseases; Results from the Turkbio Registry
Sadettin Uslu¹, Gerçek Can¹, Soner Senel², Ediz Dalkiliç³, Nevsun Inanc⁴, Servet Akar⁵, Sinem Burcu Kocaer¹, Merih Birlik¹, Sedat Capar⁶, Nurullah Akkoc⁷ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Kayseri Erciyes University, Faculty of Medicine, Kayseri, Turkey, ³Rheumatology, Uludag University Faculty of Medicine, Bursa, Turkey, ⁴Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey, ⁵Rheumatology, Izmir Katip Celebi University, School of Medicine, Rheumatology, Izmir, Turkey, ⁶Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ⁷Rheumatology, İzmir, Turkey, İzmir, Turkey
Background/Purpose: Biosimilar infliximab (CT-P13) has been used to treat patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in Turkey since 2013.The…
Abstract Number: 2503 • 2017 ACR/ARHP Annual Meeting
Does Maastricht Ankylosing Spondylitis Enthesitis Scores Differ between Ankylosing Spondylitis, Psoriatic Arthritis and Rheumatoid Arthritis Patients?
Steffan Robstad Nilssen¹, Jintana B: Andersen¹, Hanne K. Vestaby¹, Glenn Haugeberg² and Brigitte Michelsen³, ¹Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Martina Hansens Hospital, Bærum, Norway, ³Dept. of Rheumatology, Hospital of Southern Norway Trust, kristiansand, Norway
Background/Purpose: The Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) is an enthesitis index developed and validated as an outcome measure in ankylosing spondylitis (AS), but is…
Abstract Number: 1326 • 2016 ACR/ARHP Annual Meeting
Autoimmune Arthritides, Rheumatoid Arthritis, Psoriatic Arthritis, or Peripheral Spondyloarthropathy, Following Lyme Disease
Sheila Arvikar¹, Jameson Crowley¹, Katherine Sulka² and Allen C. Steere³, ¹Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Charlestown, MA, ²Rheumatology Allergy and Immunology, Massachusetts General Hospital, Charlestown, MA, ³Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Lyme arthritis (LA) usually responds to antibiotic therapy, though immune-mediated synovitis may persist after antibiotic treatment, usually confined to a previously infected joint,…
Abstract Number: 2337 • 2015 ACR/ARHP Annual Meeting
Depression, Bad Sleep Quality, and Functional Deficit Are Independently Associated with Persistent Fatigue in Arthritic Patients with Low Disease Activity Under Biological Dmards
Vitalie Nizeica¹, Myriam Normand², Delphine Denarie¹, Béatrice Pallot Prades¹, Philippe Collet¹, Adamah Amouzougan¹, Hervé Locrelle^1,2, Thierry Thomas^1,2 and Hubert Marotte^1,2, ¹Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, ²INSERM U1059/LBTO, Université de Lyon - Université Jean Monnet, Saint-Etienne, France
Background/Purpose: In rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) patients, fatigue has been mainly related to disease activity. Current management of rheumatic inflammatory diseases aims…
Abstract Number: 1837 • 2012 ACR/ARHP Annual Meeting
Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Alain Saraux¹, Jacques Benichou², Chantal Deslandre³, Loic Guillevin⁴, Latifa Idbrik⁵, Jean Sibilia⁶, Marc Soudan⁵, Daniel Wendling⁷ and Francis Guillemin⁸, ¹Rheumatology, CHU de la Cavale Blanche and Université Bretagne occidentale, Brest Cedex, France, ²INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, EA4438 Laboratoire Physiopathologie des Arthrites, Rouen, France, ³Rheumatology, Cochin Hospital, Paris, France, ⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ⁵Ecole de Sante Publique, Faculte de Medecin/BP 184, Vandoeuvre-les-Nancy, France, ⁶Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ⁷Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁸Hopitaux de Brabois, Nancy, France
Background/Purpose: Comprehensive guidelines for anti-TNFα were proposed in 2005 by the French Society for Rheumatology (SFR) in France; they did not include any economic considerations…
Abstract Number: 203 • 2012 ACR/ARHP Annual Meeting
Clinical Course Factors Associated with Outcome of Monoarthritis : A Retrospective Study of 173 Cases
Hyemin Jeong¹, Eun-Jung Park¹, Jiwon Hwang¹, Ji Young Chai², Joong Kyong Ahn³, Eun-Mi Koh⁴ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Jesang Hospital, Seongnam-si Gyeonggi-do, South Korea, ³Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea
Background/Purpose: To evaluate the clinical features and outcomes in patients with monoarthritis and to investigate predictive factors associated with the clinical course in terms of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].